AIP
ACAD icon

Arrowpoint Investment Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Arrowpoint Investment Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$727K Buy
+28,725
New +$632K 0.16% 64
2026
Q1 		– Sell
-10,011
Closed -$267K – 86
2025
Q4 		$267K Buy
+10,011
New +$239K 0.04% 90

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowpoint Investment Partners's ACAD Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 28,725 shares worth $727K. The stake represents 0.16% of the portfolio and ranks #64 among its holdings. This is a return to the name: Arrowpoint Investment Partners previously reported a position in ACAD as recently as Q4 2025.

Arrowpoint Investment Partners first reported a position in ACAD in Q4 2025 and has held it in 2 quarters since. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Arrowpoint Investment Partners held 28,725 shares of Acadia Pharmaceuticals worth $727K as of Q2 2026.
  • Acadia Pharmaceuticals was a new Arrowpoint Investment Partners position in Q2 2026.
  • Acadia Pharmaceuticals made up 0.16% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #64 holding.
  • Arrowpoint Investment Partners first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.